Stock Price

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

Light AI's smartphone diagnostic tool enters a crucial New Zealand study, but can its innovative tech overcome financial pressures and regulatory hurdles?

With the hire of LongHorn Steakhouse veteran Monika Saxena, BJ's is betting that a data-driven focus on brand and guest experience is the key ingredient.

As AeroVironment preps its year-end report, all eyes are on whether its battlefield-proven technology can meet soaring expectations amid a global arms race.

Phil McCabe, the man who built modern Naples, just made a $20M+ purchase at the new Four Seasons. It’s more than a home—it’s a signal about the future of luxury capital.

Facing sinking sales and credit downgrades, the appliance giant is swapping cheap, short-term debt for costly long-term security. A deep dive into a bold gambit.

PAVS's stock soars over 100% despite a dilutive $10M offering. A look into how a potential activewear acquisition is rewriting the narrative for this company.

A silent productivity drain is costing businesses dearly. Over half the workforce aged 40-60 is managing elder care, and the financial and career toll is immense.

The electric boat innovator executes another reverse stock split to stay on Nasdaq, but a history of similar moves raises questions about its financial health.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

The Defiance 2X Space ETF was halted amidst the SpaceX IPO frenzy, revealing the extreme volatility and complex risks of new leveraged financial products.

With projections of $22.7M from four new supplements, Cosmos Health is betting big on the US. But can its 'science-driven' platform deliver in a crowded market?

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

With CEO Reedy's sudden retirement, aerospace innovator Butler National enters a critical transition. We explore his legacy and what's next for the tech firm.

With over 4.6% of all ETH, Bitmine is not just mining crypto; it's engineering a new kind of financial institution. Is its high-stakes strategy genius or hubris?

With its new Colorado facility, USA Rare Earth aims to produce vital heavy rare earths, a critical step in the West's high-stakes bid to build a secure supply chain.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Zevia PBC appoints beverage industry veteran Alexandre Ruberti as CEO, pivoting from turnaround to 'accelerated execution' at a critical inflection point.

Beyond a steady distribution, Chartwell's latest update signals a bold repositioning strategy. What does it mean for investors and the market?